Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Official title: Dissecting and Targeting the IL-1R Pathway to Overcome Immune Evasion and Enhance Immunotherapy in Anaplastic Large Cell Lymphoma
Funded at Research Inst of Fox Chase Can Ctr · NIH-11450247 · Data updated 2026-11-12
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 6, 2021 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $441,319 |
| NIH project number | 2R01CA259188-06 |
| Project ID | NIH-11450247 on NIH RePORTER |
Who could benefit from this research
✓Could help
Eligible patients would have Anaplastic Large Cell Lymphoma and may be candidates for advanced cellular therapies in the future.
✕Less likely to help
Patients with ALCL who do not respond to immunotherapy or who cannot receive CAR therapies may not benefit.
What this research studies
This project studies why ALCL tumors often resist immune therapies and tests how blocking IL-1R signaling can enhance the effectiveness of CD30-directed CAR-T and CAR-NK cells. Researchers used genome-wide screens to identify IL-1R as a key driver of resistance and explored how IL-1R activation leads to PD-L1 maintenance and a reshaped tumor environment. The work plans to test genetic or drug inhibition of IL-1R, NFKBIZ, or IL-17F to improve tumor-killing activity of CAR therapies in ALCL. If successful, these findings could guide combination strategies to achieve more durable responses for patients.
Why it matters
Potential benefit: If the approach works, patients with ALCL could experience stronger and longer-lasting responses to CAR-based therapies.
How similar studies have gone: Prior studies have shown that combining immune pathway inhibitors with CAR therapies can improve responses in some cancers, but this ALCL-focused approach is relatively novel.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Yang, Yibin — Research Inst of Fox Chase Can Ctr
- Study coordinator: Yang, Yibin
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Targeting MALT1 to Strengthen Anti-Lymphoma Immunity and Boost Immunotherapy
Aims to improve treatment for a common type of B-cell lymphoma by blocking a specific protein (MALT1) to enhance the body's immune attack and response to existing therapies.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
NKT cell therapy for B‑cell lymphoma
This project offers an off‑the‑shelf immune cell treatment using engineered natural killer T (NKT) cells for adults with B‑cell non‑Hodgkin lymphoma.
-
Blocking MALT1 to boost the immune attack against aggressive B‑cell lymphoma
Seeing if drugs that block a protein called MALT1 can help the immune system and improve immunotherapy for adults with aggressive diffuse large B‑cell lymphoma (DLBCL).
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.